Antwerp-based HealthTeck Startup Koios hoo The observation and treatment of Parkinson’s disease has shut down € 1 million funds to accelerate its efforts to accelerate its efforts by collecting data from smartphones and smartwatchs with its AI-powered platform.
The Greek in the initial phase of the Greek Investor Ekurius, led by this round, was a number of Angel investors, including Astilab Ventures, IMEC.Start Funds and Hiban, who participated. The new fund will help Quios Care expand its digital health equipment ‘Parkioch’ in European clinics, support the regulatory exemption effort and will help build a stronger partnership with pharma companies and research institutes.
“There is an important gap between Parkinson’s true need and what they currently receive. It’s not just about handling the symptoms, it is about improving the quality of their overall living. This is here to turn off the gap quois care“Said Dr. Constantinos KiritosisCo-founder and CEO “Using the technology to clearly contact their neurologist, a patient told us, ‘Sometimes in my current drug scheme I don’t think I have no Parkinson’ ‘It is not just encouraging, it is a strong flash of what is possible. This is a conversion that we are working relentlessly to distribute for everyone who is suffering from this diseaseThe “
Established by Dr. Constantinos Kiritosis and Dr. Dimitris Ichovakis, quiz care reduces the daily life and clinical care. The solution to the team enables care teams to make previous and more personalized decisions on the basis of a purposeful, real-life proof than clinic visits or self-report.
Koios is developing an AI-powered platform that collects data inactive from smartphones and smartwatches to provide clinically meaningful insights between clinicians and researchers.
Coios Care referred to it as a “silent epidemic” – the rapid global rise of Parkinson’s disease, which is now reported to be more than ten million people. By earning data from everyday devices, the company’s goal is to personalize and improve care when facilitating clinical workfluges and supporting the development of more effective drugs.
Coios care model supports both patients and greater health care ecosystem. For physicians and patients, it provides a digital tool to guide the treatment decisions and monitor the results; For Pharma and Medtech companies, it provides a research and development platform that can produce real-world data and detect meaningful last points for clinical trials.
“For a long time, patients, physicians and researchers lack the care of Parkinson’s care to be truly personalized and to understand the impact of the real life of the disease and to understand its treatments, lack of purposeful data“Said Dr. IkovakisCoios Care co-founder and CTO. “This fund reflects the urgent need for a new quality in care. With our solution, we give patients to better understand their condition, to equip the treatment teams with unprecedented insights and provide a strong tool to provide a more effective therapy developmentThe “
So far, Coios Care has studied 5 patients in a multi-centers EU examination and is working with hospital pilot sites and industrial partners across Europe. The platform is integrated with the current regulatory guidance in digital health equipment and designed to improve treatment and improve trial success rates reflecting the results of the real-world patient.
Alex VambacasEvalurius VC’s partner, commented, “Game-verazer for neurodizerrative disorders in the innovative method of quoos care to monitor the quality of life with daily devices. We enable the team’s scientific hardness, clinical validity and long-term neurodynagonal terms and enable the transfer of personalized, data-driven diseases to the scale.
“In Greece and Belgium, with roots and allies across Europe, quizcare such as bridges, discipline, extensive, influence-driven innovation, which can unlock the more connected European diptech ecosystem.The “
Looking forward to the front, the Cairo Care Drug-Devis plans to develop products and expand its expansion to other brain and behavior-related conditions, including light cognitive weaknesses, alzheimerus, narcoscio and eating disorders. Startup is targeting areas where real-time, real-world data remains an important missing link in care and research.
[publish_date
